Description

This program covered the latest topics in cardiovascular and metabolic disease, guidelines, late-breaking clinical trial results, and addressed patient care issues encountered in daily practice.

Learning Objectives

Following participation in this program, participants will be able to:

Session 1

• Describe challenges with anticoagulation in patients with comorbidities
• Identify how to appropriately diagnose and manage MINOCA (Myocardial Ischemia without obstructive CAD
• Select the appropriate treatment for the management of CKD
• Examine the clinical decisions for the selection of Finerenone to treat CKD

Session 2

• Describe appropriate management strategies for heart failure
• Recognize the importance of lipid-related risk reduction
• Consider the role of PCSK9 inhibitors and colchicine for patients following an MI
• Determine the role of Lp(a) for cardiovascular risk stratification

Session 3

• Identify the role of medical nutrition therapy to support the management of obesity.
• Develop an effective management strategy for NAFLD that considers potential risks and benefits of therapeutic options.
• Summarize the role of Semaglutide in reducing CV risk
• Explore new and future treatments for the management of obesity

Planning Committee

• Milan Gupta, MD, FRCPC, FCCS, FACC, FAHA
• Robert A. Hegele, MD, FRCPC, FACP, FAHA, FCAHS
• Christine Palmay, MD, CCFP
• Anil Maheshwari, MD, CCFP, DABOM, DABFM
• Laura Reardon, MD, CCFP, ABOM Diplomate

Faculty

• Andrew Ha, MD, MSc, FRCPC
• Tara Sedlak, MD, FRCPC, MBA
• Kim Connelly, MD, PhD, MBBS, FSCMR, FCCS
• Jordan Weinstein, MD, FRCPC
• Stephanie Poon, MD, MSc, FRCPC
• Robert Hegele, MD, FRCPC, Cert Endo, FACP
• Michelle O'Donoghue, MD, MPH
• Jennifer Brown, MSc., RD, CBE
• Magnus McLeod, MD, FRCPC, DRCPSC
• Megha Poddar, MD, FRCPSC